MetaCap

Neogen Earnings

NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

10.55-0.30 (-2.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Neogen earnings summary

In its most recent report on Oct 6, 2026 (Aug/2026), NEOG posted EPS of $-0.05 versus the $0.04 consensus estimate, a negative surprise of 225.0%. Revenue for the quarter was $222.8 million. Quarterly EPS is down 129.4% from the same quarter a year earlier.

Across the last 16 reports, NEOG shares moved an average of 4.9% (in either direction) in the first trading session after results, rising 6 times and falling 10 times.

Summary generated from market data by MetaCap's automated system. Methodology

NEOG earnings history

Neogen reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Oct 6, 2026$0.04$-0.05-225.0%-0.3%
Jul 30, 2026—$-0.06—-4.7%
Apr 9, 2026—$-0.08—+1.0%
Jan 8, 2026—$-0.07—-3.8%
Oct 9, 2025—$0.17—-2.6%
Jul 30, 2025—$-2.82—+9.0%
Apr 9, 2025—$-0.05—-21.3%
Jan 15, 2025—$-2.10—-0.8%
Oct 10, 2024—$-0.06—+0.5%
Jul 30, 2024—$-0.02—+2.6%
Apr 9, 2024—$-0.01—-6.2%
Jan 9, 2024—$-0.02—-6.5%
Oct 10, 2023—$0.01—-2.7%
Aug 15, 2023—$-0.02—+1.1%
Apr 4, 2023—$0.04—-5.9%
Jan 9, 2023—$-0.19—+9.9%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related